Molecular Imaging and Biology

, Volume 11, Issue 4, pp 236–240

Limitations of Small Animal PET Imaging with [18F]FDDNP and FDG for Quantitative Studies in a Transgenic Mouse Model of Alzheimer’s Disease

  • Claudia Kuntner
  • Adam L. Kesner
  • Martin Bauer
  • Robert Kremslehner
  • Thomas Wanek
  • Markus Mandler
  • Rudolf Karch
  • Johann Stanek
  • Tanja Wolf
  • Markus Müller
  • Oliver Langer
Brief Article

DOI: 10.1007/s11307-009-0198-z

Cite this article as:
Kuntner, C., Kesner, A.L., Bauer, M. et al. Mol Imaging Biol (2009) 11: 236. doi:10.1007/s11307-009-0198-z

Abstract

Purpose

We evaluated the usefulness of small animal brain positron emission tomography (PET) imaging with the amyloid-beta (Aβ) probe 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malonitrile ([18F]FDDNP) and with 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) for detection and quantification of pathological changes occurring in a transgenic mouse model of Alzheimer’s disease (Tg2576 mice).

Procedures

[18F]FDDNP (n = 6) and FDG-PET scans (n = 3) were recorded in Tg2576 mice (age 13–15 months) and age-matched wild-type litter mates. Brain volumes of interest were defined by co-registration of PET images with a 3D MOBY digital mouse phantom. Regional [18F]FDDNP retention in mouse brain was quantified in terms of the relative distribution volume (DVR) using Logan’s graphical analysis with cerebellum as a reference region.

Results

Except for a lower maximum brain uptake of radioactivity in transgenic animals, the regional brain kinetics as well as DVR values of [18F]FDDNP appeared to be similar in both groups of animals. Also for FDG, regional radioactivity retention was almost identical in the brains of transgenic and control animals.

Conclusions

We could not detect regionally increased [18F]FDDNP binding and regionally decreased FDG binding in the brains of Tg2576 transgenic versus wild-type mice. However, small group differences in signal might have been masked by inter-animal variability. In addition, technical limitations of the applied method (partial volume effect, spatial resolution) for measurements in such small organs as mouse brain have to be taken into consideration.

Key words

Alzheimer’s disease (AD) PET [18F]FDDNP FDG Transgenic mouse Amyloid-beta (Aβ) 

Copyright information

© Academy of Molecular Imaging 2009

Authors and Affiliations

  • Claudia Kuntner
    • 1
  • Adam L. Kesner
    • 5
  • Martin Bauer
    • 2
  • Robert Kremslehner
    • 1
    • 6
  • Thomas Wanek
    • 1
  • Markus Mandler
    • 4
  • Rudolf Karch
    • 7
  • Johann Stanek
    • 1
  • Tanja Wolf
    • 3
  • Markus Müller
    • 2
  • Oliver Langer
    • 1
    • 2
  1. 1.Department of Radiopharmaceuticals & microPET ImagingAustrian Research Centers GmbH—ARCSeibersdorfAustria
  2. 2.Department of Clinical PharmacologyMedical University of ViennaViennaAustria
  3. 3.Department of ToxicologyAustrian Research Centers GmbH—ARCSeibersdorfAustria
  4. 4.AFFiRiS GmbHViennaAustria
  5. 5.Department of Molecular and Medical Pharmacology, David Geffen School of MedicineUCLALos AngelesUSA
  6. 6.Institute of Solid State PhysicsUniversity of TechnologyViennaAustria
  7. 7.Department of Medical Computer SciencesMedical University of ViennaViennaAustria

Personalised recommendations